4W6 Stock Overview
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Theradiag SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.25 |
| 52 Week High | €2.30 |
| 52 Week Low | €1.16 |
| Beta | -0.27 |
| 11 Month Change | -7.78% |
| 3 Month Change | -42.36% |
| 1 Year Change | -45.27% |
| 33 Year Change | -51.74% |
| 5 Year Change | n/a |
| Change since IPO | -49.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4W6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -0.2% | -0.5% |
| 1Y | -45.3% | -0.1% | 1.6% |
Return vs Industry: 4W6 underperformed the German Medical Equipment industry which returned 9.8% over the past year.
Return vs Market: 4W6 underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| 4W6 volatility | |
|---|---|
| 4W6 Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4W6's share price has been volatile over the past 3 months.
Volatility Over Time: 4W6's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 61 | Simon Daviere | www.theradiag.com |
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. The company offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. It also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer.
Theradiag SA Fundamentals Summary
| 4W6 fundamental statistics | |
|---|---|
| Market cap | €16.44m |
| Earnings (TTM) | €421.92k |
| Revenue (TTM) | €13.51m |
39.0x
P/E Ratio1.2x
P/S RatioIs 4W6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4W6 income statement (TTM) | |
|---|---|
| Revenue | €13.51m |
| Cost of Revenue | €7.24m |
| Gross Profit | €6.26m |
| Other Expenses | €5.84m |
| Earnings | €421.92k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 46.37% |
| Net Profit Margin | 3.12% |
| Debt/Equity Ratio | 17.1% |
How did 4W6 perform over the long term?
See historical performance and comparison